Oncternal Therapeutics Inc ONCT
€0.53
Last Updated: Mar 24, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Oncternal Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of ONCT Stock
Germany Health Care Nano Cap No. As of September 2026, Oncternal Therapeutics Inc (ONCT) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Oncternal Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
ONCT Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Oncternal Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Oncternal Therapeutics Inc (ONCT) Chart
Financial Metrics & Statements of Oncternal Therapeutics Inc (ONCT)
FAQ's for Oncternal Therapeutics Inc (ONCT)
- As of September 2026, Oncternal Therapeutics Inc ONCT is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Oncternal Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Oncternal Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Oncternal Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Oncternal Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Oncternal Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Oncternal Therapeutics Inc (ONCT)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
